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Background: While there is some consensus on methods for investigating statistical and methodological
heterogeneity, little attention has been paid to clinical aspects of heterogeneity. The objective of this study is to
summarize and collate suggested methods for investigating clinical heterogeneity in systematic reviews.
Methods: We searched databases (Medline, EMBASE, CINAHL, Cochrane Library, and CONSORT, to December 2010)
and reference lists and contacted experts to identify resources providing suggestions for investigating clinical
heterogeneity between controlled clinical trials included in systematic reviews. We extracted recommendations,
assessed resources for risk of bias, and collated the recommendations.
Results: One hundred and one resources were collected, including narrative reviews, methodological reviews,
statistical methods papers, and textbooks. These resources generally had a low risk of bias, but there was minimal
consensus among them. Resources suggested that planned investigations of clinical heterogeneity should be made
explicit in the protocol of the review; clinical experts should be included on the review team; a set of clinical
covariates should be chosen considering variables from the participant level, intervention level, outcome level,
research setting, or others unique to the research question; covariates should have a clear scientific rationale; there
should be a sufficient number of trials per covariate; and results of any such investigations should be interpreted
with caution.
Conclusions: Though the consensus was minimal, there were many recommendations in the literature for
investigating clinical heterogeneity in systematic reviews. Formal recommendations for investigating clinical
heterogeneity in systematic reviews of controlled trials are required.Background
Systematic reviews sometimes apply statistical techni-
ques to combine data from multiple studies resulting in
a meta-analysis. Meta-analyses result in a point estimate,
the summary treatment effect, together with a measure
of the precision of results (e.g., a 95% confidence inter-
val). These measures of precision represent the degree of
variability or heterogeneity in the results among
included studies. There are several possible sources of
variability or heterogeneity among studies that are
included in meta-analyses. Variability in the participants,
the types or timing of outcome measurements, and* Correspondence: jgagnier@umich.edu
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reproduction in any medium, provided the orintervention characteristics may be termed clinical het-
erogeneity; variability in the trial design and quality is
typically termed methodological heterogeneity; variabil-
ity in summary treatment effects between trials is
termed statistical heterogeneity [1]. Methodological and
clinical sources of heterogeneity contribute to the mag-
nitude and presence of statistical heterogeneity [1].
Methodological heterogeneity hinges on aspects of im-
plementation of the individual trials and how they differ
from each other. For example, trials that do not ad-
equately conceal allocation to treatment groups may re-
sult in overestimates in the meta-analytic treatment
effects [2]. Significant statistical heterogeneity arising
from methodological heterogeneity suggests that the
studies are not all estimating the same effects due to dif-
ferent degrees of bias.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ticipant characteristics (e.g., sex, age, baseline disease se-
verity, ethnicity, comorbidities), types or timing of
outcome measurements, and intervention characteristics
(e.g., dose and frequency of dose [1]). This heterogeneity
can cause significant statistical heterogeneity, inaccurate
summary effects and associated conclusions, misleading
decision makers and others. As such, systematic
reviewers need to consider how best to handle sources
of heterogeneity [1]. For example, preplanned subgroup
analyses, stratifying for similar characteristics of the
intervention and participants, could tease-out important
scientific and clinically relevant information [3].
Systematic reviews are frequently recognized as the
best available evidence for decisions about health-care
management and policy [3-7]. Results of systematic
reviews are often incorporated into clinical practice
guidelines [5] and required in funding applications by
granting agencies [6]. In spite of all this it appears
health-care professionals and policy makers infrequently
use systematic reviews to guide decision-making [8].
A limitation of many systematic reviews is that their
content and format are frequently not useful to decision
makers [8]. For example, while some guidance exists de-
scribing what to include in reports of systematic reviews
(e.g., the PRISMA statement [9]), characteristics of the
intervention that are necessary to apply their findings
are infrequently provided [10-13]. This has led to some
preliminary work on how to extract clinically relevant
information from systematic reviews [14]. Furthermore,
systematic reviews commonly show substantial hetero-
geneity in estimated effects (statistical heterogeneity),
possibly due to methodological, clinical or unknown fea-
tures in the included trials [15]. While guidance exists
on the assessment and investigation of methodological
[1] and statistical heterogeneity [1,16], little attention
has been given to clinical heterogeneity.
We report a systematic review of suggested methods
for investigating clinical heterogeneity in systematic
reviews of controlled clinical trials. We also provide
some guidance for systematic reviewers.
Methods
This project identified resources giving recommenda-
tions for investigating clinical heterogeneity in systematic
reviews. We extracted their recommendations, assessed
their risk for bias, and categorized and described the
suggestions.
Search
The following databases were searched: Medline (to
October 29, 2010), EMBASE (to Oct 30, 2010), CINAHL
(1981 to Oct 30, 2010), Health Technology Assessment
(to Oct 29, 2010), the Cochrane Methodology Register(to Oct 29, 2010), and the CONSORT database of meth-
odological papers (to October 30, 2010). A library and in-
formation scientist was consulted to create sensitive and
specific searches, combining appropriate terms and
extracting new terms from relevant studies for each data-
base. The following search terms were used in the vari-
ous databases and at various stages of the search:
heterogeneity, applicability, clinical, assessment, check-
list, guideline(s), scale, and criteria. The “adjacent” or
“within X words” tools were used for the terms “clinical”
and “heterogeneity” for all databases. In addition, we
used the PubMed related-links option that identifies
indexed studies on similar topics or having similar index-
ing terms to include a broad range of papers that might
be indirectly related to clinical heterogeneity. Appendix
A contains details of the electronic searching. One inves-
tigator (JG) contacted representatives of the Cochrane
Collaboration, the Campbell Collaboration, the Agency
for Healthcare Research and Quality (AHRQ) and a se-
lection of experts identified through an initial review of
the literature to suggest relevant articles, guidelines, pos-
ition papers, textbooks or other experts in the area. We
also reviewed the Cochrane Handbook, the Campbell
Collaboration methods guides, and the AHRQ compara-
tive effectiveness section for any guidance on clinical het-
erogeneity and searched reference lists of all retrieved
resources.
The overall process consisted of a “snowballing” tech-
nique of seeking information on the topic, by which we
asked experts to refer us to other experts or resources,
and so on, until each new resource yielded a negligible
return. Several individuals with expertise in the area of
systematic reviews (JG, DM, JB, CB) met to identify key
textbooks to include out of thier personal knowledge of
textbooks in the area. These individuals presented what
each felt were key textbooks in the area and then
debated the merits of each, finally coming to a
consensus-based decision on which to include. In gen-
eral, these methods allowed us to include a broad array
of resources related to investigating clinical heterogen-
eity in systematic reviews.Inclusion criteria
Clinical heterogeneity is defined as differences in partici-
pant, treatment, or outcome characteristics or research
setting. We included any methodological study, system-
atic review, guideline, textbook, handbook, checklist,
scale, or other published guidance document with a
focus on assessing, measuring, or generally investigating
clinical heterogeneity between or within controlled clin-
ical trials included in systematic reviews. This included
quantitative, qualitative, graphical or tabular techniques,
suggestions or methods.
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Systematic reviews of interventions for efficacy were
excluded.
Data extraction
A data extraction form was developed and piloted inde-
pendently by two individuals (JG, DM) on a random se-
lection of 10 included resources. Extractions were
checked for consensus and the form revised according to
the feedback provided. One person extracted information
for all included studies (JG) regarding why the authors
sought to assess clinical heterogeneity; what “criteria”
were used to assess clinical heterogeneity; how these
were developed; the definition of clinical heterogeneity
used by the authors; any graphical, tabular or other dis-
play/summary methods; statistical recommendations;
reported methods used; empirical validation performed
on the “criteria”; examples of implementing the methods;
and recommendations on how the assessments are to be
used in systematic reviews. All extractions were checked
for accuracy by another individual (DM).
Synthesis methods
We thematically grouped the retrieved resources, sug-
gestions or techniques (e.g., statistical versus qualitative456 full texts reviewed for inclusion
101 included
a. PubMed, HTA, Cochrane Methodology register (t
2010): N = 612 
b. EMBASE (1980 to Oct. 30, 2010): N = 930 
c. CINAHL (EBSCO) (1981 to Oct. 30, 2010): N = 
d. PubMed related-links for 3 references(16,20,66): N
e. CONSORT Database (Up to Oct 30th, 2010): N = 
citations 
f. Text books: N = 5 
Total N = 2497 titles and abstracts reviewed 
Expert contact: N = 5 unique papers 
Reference list review: N = 1 unique 
paper
Figure 1 Search and inclusion results.recommendations), described the recommendations,
highlighted any empirical support cited for each recom-
mendation, and made an overall summary of the
recommendations.
Assessment of method validation
Four individuals (JG, DM, JB, CB) met several times to
discuss how to rate the variety of resources retrieved.
These individuals came to a consensus that there were
several classes of resources that did not have any accepted
risk-of-bias assessment tools or instruments (e.g., text-
books, narrative reviews, learning guides, expert opinions).
Therefore instead, of assessing “risk of bias” of these arti-
cles, we chose to determine if specific methods have been
validated. Resources were considered validated if they had
a clear rationale or reported empirical evidence for that
recommendation (e.g., reference to previous empirical
work or a test of the method with empirical or simulated
data). One individual (JG) assessed the method of valid-
ation of each of these included resources.
Results
Our searches identified 2497 unique titles and abstracts;
after screening, 101 papers were included in the review
[17-117]. These resources included statistical papers,• 462 excluded due to being 
duplicates
• 1450 excluded due to being 
systematic reviews of 
interventions 
• 135 excluded due to not being 
on clinical heterogeneity
hrough Oct. 29, 
188 
 = 762 
0 additional 
• 12 not related to SRs of 
controlled trials 
• 2 not available 
• 1 duplicate 
• 340 excluded due to not 
offering suggestions related to 
clinical heterogeneity 
Table 2 Types of clinical covariates suggested across all
resources
General Category Specific
Covariate
Number of
Resources
Recommending1
Patient level General2 15
Age 7
Baseline severity 3
Sex/gender 4
Ethnicity 2
Comorbidities 2
Other disease features 2
Intervention level General 13
Dose 8
Duration 5
Brand 3
Co-interventions 3
Intensity 3
Timing 3
Route 2
Compliance 2
Others unique to the
intervention
2
Frequency 1
Comparator/control 1
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nions, learning guides, consensus-based guidelines and
textbooks. Figure 1 describes details of the search and
screening results. The very few disagreements on inclu-
sion were easily resolved through discussion. Sixty-four
(64.6%) of the resources (statistical, methodological, con-
sensus guideline resources) were assessed for validation.
Forty-one (64.1%) of these references were evaluated as
being sufficiently validated.
Table 1 describes some basic characteristics of the
included resources. The most common type of re-
source was statistical papers (42.4%), with narrative
reviews/expert opinion papers being the next most
common (29.3%). Most of the papers were published
in the 2000s (70.1%), and statistical methods for inves-
tigating clinical heterogeneity were the most frequent
types of suggestions across resources (73.7%). Table 2
reports a list of clinical variables suggested for investi-
gating clinical heterogeneity and the number and types
of resources suggesting each. General suggestions of
clinically related variables, without identification of
specific clinical covariates, were the most common
across all included resources. Most suggestions were
within distinct categories: participant level (e.g., age),
intervention level (e.g., dose), or outcome level (e.g.,
event type, length of follow-up) covariates. A number
of resources (N = 14) reported control event rate/base-
line risk as being a covariate worth investigating.Table 1 Descriptive characteristics of included resources
that reported recommendations for investigating clinical
heterogeneity in systematic reviews of controlled clinical
trials (N= 101)
Descriptive Characteristics N1
Type of publication Statistical paper 44
Narrative review or
expert opinion
29
Methodological review 14
Consensus-based guideline 9
Textbook 5
Decade of publication 2000s 70
1990s 27
1980s 4
Guidance on statistical
methods
75
Clinical variables
(general2 or specific)
recommended
39
Process for choosing
clinical variables recommended
28
1. The number (N) of resources equals the percentage of resources since we
include 101 total resources.
2. The term “general” means that the resource listed the term “patient”,
“intervention”, or “outcome” as a category from which to consider covariates
without suggesting specific variables.
Outcome level General 6
Event type 5
Length of follow-up 4
Outcome measure type 3
Outcome definition 3
Timing 2
Repeated outcome
measurements
1
Control event rate /
baseline risk
14
Research setting 4
Comparison conditions 3
Early stopping rules 1
Population risk 1
1. The number (N) of resources equals the percentage of resources since we
include 101 total resources.
2. The term “general” means that the resource listed the term “patient”,
“intervention”, or “outcome” as a category from which to consider covariates
without suggesting specific variables.Table 3 lists recommendations regarding the process
of choosing clinical characteristics to investigate. Five or
more resources suggested the following: a priori choice
of clinical covariates (e.g., in the review protocol); look
at forest plots for trials that may contribute to hetero-
geneity and then look for clinical characteristics therein;
Table 3 Recommendations regarding the methods of choosing or identifying clinical covariates for investigation and
interpretation of the findings
General Category of
Recommendation
Specific Recommendation Number of
Resources1
Citations
When to identify covariates
in the review process
A priori (e.g., in protocol) 17 76, 92,93,95, 100, 98, 18, 26, 39,
40, 30, 59, 29, 31, 46, 94, 114
How to find important
clinical covariates from
trial information
Looking at forest plots
(variation in point estimates/CI
overlap/ adding a
vertical line for levels of
some clinical variable)
6 92, 98, 93, 97, 98, 94
Proceed regardless of formal
testing of statistical
heterogeneity
5 35, 92, 97, 98, 29
Looking at L’Abbe plots 4 98, 45, 93, 98
Influence plot 3 98, 54, 85
Looking at summary tables 2 92, 24
Looking at funnel plots 2 49, 98
Use conceptual frameworks to
facilitate choice of covariates
(i.e., using taxonomies for
active ingredients)
2 98, 112
I2 (look at the change in
statistical heterogeneity by
adding subgroups)
2 87, 100
Plot of effect size against
individual covariates
1 48
Using an adaptation of
multidimensional
scaling (CoPlot)
1 55
Plot of normalized z-scores 1 93
Radial/Galbraith plot 1 93
Frequency distributions 1 98
Dose-response graph 1 3?
Use P.I.C.O. model to guide
choice of characteristics
1 115
Use causal mediating
processes
1 113
Treat strata within trials as
separate studies; these
subgroups if similar across
studies can be combined
1 46
Rationale for choice
of covariate
Scientific (e.g.,
pathophysiological,
pharmacologic argument)
10 7,76,92,93, 100, 18, 26, 59, 31, 115
Previous research
(e.g., large RCT)
3 76, 68, 100
Clinical grounds 2 96, 100
Indirect evidence 1 59
Personnel Use of clinical experts 2 21, 115
Blind to results of trials 1 35
Number of
covariates/
trials needed
Small number of covariates 7 92, 95, 100, 18, 26, 31, 94
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Table 3 Recommendations regarding the methods of choosing or identifying clinical covariates for investigation and
interpretation of the findings (Continued)
Each covariate investigation
should be based on an
adequate number of studies
(e.g., 10 for every moderator)
6 100, 59, 50, 94, 115
Investigators must report
actual number of covariates
investigated for reader to
determine the potential for
false-positives
1 115
Number of outcomes
to investigate
Restrict investigations to small
number of outcomes
(e.g., primary)
1 26
Limit to central question in
the analysis
1 94
Interpretation of results
of investigations
Use caution (4 resources note
especially with post hoc
testing)
12 100, 18, 29, 31, 85, 16, 20, 23, 25, 61, 32, 35
Observational only 6 59, 23, 94, 98, 100, 114
Exploratory or hypothesis
generating only
4 32, 100, 40, 94
Consider confounding
between covariates
4 100, 50, 115, 59
Consider artifactual causes of
between-study variation
2 6, 98
Consider biases (e.g.,
misclassification,
dilution, selection)
2 93, 115
Look at magnitude of the
effect and the 95% CI; not just
effect and p-value; consider
precision of the subgroup
effects (e.g., sample sizes in
the studies dictate precision of
the subgroup effects)
2 100, 115
Seek evidence to justify claims
of subgroup findings
1 26
Identify knowledge gaps in
the investigations
1 24
Consider effect of variability
within studies
1 19
Consider if the magnitude
is clinically important (i.e.,
differences in effect between
subgroups)
1 100
Think through causal
relationships, especially
directionality
1 113
Use caution with variables
grouped after randomization
1 23
Consider parabolic
relationships (i.e., beyond
linear regression)
1 115
Be cautious not to say there is
a consistency of effect if no
subgroup effects are found
1 115
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Table 3 Recommendations regarding the methods of choosing or identifying clinical covariates for investigation and
interpretation of the findings (Continued)
Descriptive methods Perform a narrative synthesis
of these investigations
4 115, 98, 27, 100
Other: 1. idea webbing, 2.
qualitative case descriptions, 3.
investigator/methodological/
conceptual triangulation
1 98
Use of types of data Aggregate patient data for trial
level covariates
4 23, 25, 118, 46
Only group characteristics
derived prior to randomization
(e.g., stratifying)
2 23, 46
Individual patient data for
participant level covariates
1 59
Individual patient data only for
all covariates where possible
1 59
1. The number (N) of resources equals the percentage of resources since we include 101 total resources.
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testing for statistical heterogeneity; base clinical covari-
ates on a clear scientific rationale (e.g., a pathophysio-
logical argument); investigate a small number of
covariates; base each covariate suggestion on an ad-
equate number of trials (e.g., 10 trials was a common
suggestion); use caution when interpreting the findings
of investigations; consider the results of such investiga-
tions as exploratory, hypothesis generating and observa-
tional; and consider confounding between covariates.
Table 4 summarizes the types of statistical methods
suggested for investigating clinical heterogeneity charac-
teristics and the number of resources suggesting each.
Many included resources made some mention of stat-
istical methods of investigating aspects of clinical het-
erogeneity (N= 69/99, 69.7%). Also, many of these
resources made general suggestions regarding the use of
subgroup analyses (N= 18) and meta-regression (N= 16);
however, the majority of these did not offer any specific
recommendations. A wide variety of meta-regression
techniques were suggested, many of which included
simulated evidence or other forms of empirical testing.
Several Bayesian approaches were suggested as well as
several methods for individual patient data analysis
[34,48,58,63,66,69,71,75,95]. Four textbooks appeared to
be relatively comprehensive in their treatment of statis-
tical recommendations [93-95,114].
Overall, we felt that there was some consensus across
the resources regarding planning investigations, the use
of clinical expertise, the rationale for choice of covariate,
how to think through types of covariates, making a cov-
ariate hierarchy, post hoc covariate identification, statis-
tical methods, data sources and interpretation of
findings (See Table 5). We summarize the common
recommendations that appeared in the literature to offer
some preliminary guidance for systematic reviewers inTable 5 and we elaborate on several key areas in the dis-
cussion section below.
Sources appearing to be the most comprehensive in
their discussion of recommendations for investigating
clinical heterogeneity included the Cochrane Handbook
[100] and the Centre for Reviews and Dissemination’s
Guidance For Undertaking Reviews In Health Care [98]
and the AHRQ Comparative effectiveness review meth-
ods: clinical heterogeneity [115].
Discussion
A variety of decisions must be made when performing a
systematic review. One such decision is how to deal
with obvious differences among and within trials.
Though a significant test for the presence of statistical
heterogeneity (e.g., Q test) and a large degree of hetero-
geneity (e.g., I2 > 75%) might obligate a reviewer to look
for covariates to explain this variability, a nonsignificant
test or a small I2 (e.g., <25%) does not preclude the
need to investigate covariate treatment effect interac-
tions [35,92,97,100]. That is, even with low statistical
heterogeneity, there may still be factors that influence
the size of the treatment effect, especially if there is a
strong argument (i.e., pathophysiologic or otherwise)
that some variable likely does have such an influence.
Observed or expected heterogeneity of treatment
effects can be handled in several ways. The heterogeneity
can be ignored and a meta-analysis conducted with a
fixed-effects or random-effects model, or one can at-
tempt to explain the heterogeneity through subgroup
analyses, meta-regression or other techniques [25]. The
latter moves the review away from overall statements of
evidence to increasingly clinically applicable results and
conclusions as well as new hypotheses for future re-
search [75]. Anello and Fleiss [28] make a clear distinc-
tion between meta-analyses with a goal of arriving at a
Table 4 Statistical suggestions for investigating aspects of clinical heterogeneity
General Category of
Statistical Method
Specific Method Suggested Number of
Resources1
Citations
Subgroup analyses General 18 60, 2324, 25,46, 48, 50, 75, 92, 94,
93, 27, 97, 100, 98, 115, 105, 19
Hierarchical testing procedure
based on the heterogeneity
statistic Q
1 114
Combining subgroups across
studies (i.e., in stratified
studies)
1 114
Moderator Analyses
1. ANOVA2 analogue
(e.g., a categorical moderator)
4 48, 94, 95, 114
2. Meta-regression General mention 16 19, 60, 6, 24, 2528, 31,32,43, 50,
75, 94, 95, 100, 98, 93, 1325, 418
Fixed effects model (general) 4 92, 93, 94, 95
Bayesian models (general) 4 66, 71, 124, 95
New maximum likelihood
method
2 60, 124
New weighted least squares
model
2 58, 67
Random effects model
(general)
2 67, 114
Random effects model for IPD3 2 58, 61
Permutation-based resampling 2 31, 43
Other nonparametric (e.g.,
fractional polynomials, splines)
2 69, 85
Mixed effects model 2 38, 114
New variance estimators
(for covariates)
2 77, 84
Methods for measurement of
residual errors
2 59, 41
Bayesian model in the
presence of missing study-
level covariate data
1 110
Semi-parametric modeling
(general)
1 80
Fixed effects generalized least
squares model
1 68
Hierarchical regression models 3 60, 64, 124
Random effects model with
new variance estimator
1 70
Logistic regression with binary
outcomes
1 25
Interaction term for meta-
regression model
1 95
Consider nonlinear
relationships (e.g., use
quadratic or log
transformations)
1 48
Bayesian model for use in
meta-analyses of multiple
treatment comparisons
1 111
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Table 4 Statistical suggestions for investigating aspects of clinical heterogeneity (Continued)
3. Multivariate analyses 1 48
4. Multiple univariate analyses
with Bonferroni adjustments
1 48
5. Meta-analysis of interaction
estimates
1 61
6. Model to include the
repeated observations
(time as a variable) using IPD
1 109
7. Z test 1 125
Bayesian Approaches
1. Hierarchical Bayesian
modeling
2 44, 48
2. Random effects models 1 63
Data Specific Approaches
1. IPD analyses General 5 75, 76, 95, 97, 23
Regression 1 61, 46
Adding a treatment-
covariate interaction term
1 95
2. Combination of IPD & APD4 Two-step models 2 74, 78
Multi-level model 2 69, 100
Meta-analysis of
interaction estimates
1 61
Other Approaches
Models for control event rate /
baseline risk
General (e.g., control
event rate)
10 63, 24, 71, 81, 79, 93, 100, 19, 78, 111
Structural equation modeling
(SEM)
Integration of SEM with fixed,
random and mixed effects
meta-analyses
1 42
Mixed treatment comparisons
combined with
meta-regression
1 72
Combining regression
coefficients from
separate studies
1 64
1. The number (N) of resources equals the percentage of resources since we include 101 total resources; 2. ANOVA= analysis of variance; 3. IPD = individual patient
data; 4. APD= aggregate patient data.
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analyses”) and those focused on explaining why the ef-
fect sizes vary (“exploratory or causal meta-analyses”).
The choice between these depends on the objective of
the review, but it is clear that meta-analyses are more
applicable to decision making (e.g., clinical, policy) when
they are exploratory in nature [14,28,53,75,99]. The trials
included in a systematic review may be so very similar
that the summary effect estimate is the most reasonable
and applicable metric [114]. But these cases are very
rare, and therefore we would expect most questions
asked and tested through meta-analytic methods should
concern possible reasons for variation in effect [114].
Many resources were found that suggested methods
for carrying out investigations of clinical heterogeneity
in systematic reviews [17-102]. There was great varietyin the types of resources identified (statistical papers to
commentaries) and in their potential for risk of bias. It
was decided early to include any resource, no matter the
design, methods, or publication type. For this reason
many of the included resources might normally be con-
sidered at a high risk of bias (e.g., narrative reviews, ex-
pert opinions, learning guides and commentaries) and
thus providing suggestions of questionable validity. But
it was felt that these types of resources might provide
the most valuable information on the subject of clinical
heterogeneity. That is, investigating, and in particular
choosing which clinical characteristics to investigate,
requires clinical expertise, or at a minimum, knowledge
of empirical evidence of some covariate of importance.
The inclusion of these resources could be viewed as a
drawback, but we saw it as a strength of this research. It
Table 5 Summary of recommendations for investigating
clinical heterogeneity in systematic reviews
Recommendation Category Recommendation Description
A-priori planning 1. All plans for investigating clinical
heterogeneity should be made explicit,
a-priori (e.g., in the protocol for the
systematic review).
Clinical expertise 2. The review/investigative team should
include clinical experts or state a plan
for consulting clinical experts during the
review protocol development and
implementation (e.g., when choosing
clinical covariates and when
interpreting the findings).
Covariate rationale 3. Clinical covariates should be chosen
that have a clearly stated rationale for
their importance (e.g., a
pathophysiological argument, reference
to the results of a previous trial).
Thinking through
covariate categories
4. Review teams should think through
the following categories to determine if
related covariates might logically
influence the treatment effect in their
particular review: participant level,
intervention level, outcome level,
research setting, or others unique to
their research question.
Covariate hierarchy 5. A logical hierarchy of clinical
covariates should be formed and
investigated only if there is sufficient
rationale and a sufficient number of
trials available (10 trials per covariate).
Post hoc covariate
identification
6. State any plans to include additional
covariates after looking at the data
(post hoc) from included studies (e.g.,
forest plots, radial plots) and how they
plan to do this.
Statistical methods 7. Describe a-priori the statistical
methods proposed to investigate
identified covariates. Refer to accepted
texts or published papers in the area to
be sure to implement these methods in
a valid manner. Include an individual
with experience in conducting these
analyses.1
Data sources 8. Aggregate patient data: Reasonable
for investigating trial level covariates
9. Individual patient data: Consider
when investigating participant level
covariates (otherwise results are subject
to ecologic bias)
Interpretation 10. A. Protocol: Describe how the results
of any findings are going to be
interpreted and used in the overall
synthesis of evidence.
B. Review: Consider the observational
nature of these investigations; consider
confounds and important potential
biases; consider magnitude of the
effect, confidence intervals and
directionality of the effect.
1 We do not provide detailed recommendations for statistical analyses here
because of the breath and complexity of this topic. Instead we suggest that
one refer to accepted resources and well-trained individuals with expertise in
the area.
Gagnier et al. BMC Medical Research Methodology 2012, 12:111 Page 10 of 15
http://www.biomedcentral.com/1471-2288/12/111was these resources that provided most of the sug-
gestions regarding the methods for choosing or iden-
tifying clinical covariates to investigate (Table 3). The
consensus-based guidelines provided most of the sugges-
tions regarding the process of choosing or identifying
clinical covariates, and the statistical papers, as might be
expected, covered the majority of the specific statistical
suggestions; but the textbooks also offered many sugges-
tions in both areas. There was some consensus across
resources, but only a small number of resources
included a relatively comprehensive set of recommenda-
tions [15,93,94,98]. Therefore, future research should be
directed at developing a comprehensive and up to date
set of guidelines to aid reviewers in investigating clinical
heterogeneity. We summarize the common recommen-
dations that appear in the literature to offer some pre-
liminary guidance for systematic reviewers (Table 5).
We were surprised to see that the term clinical hetero-
geneity was relatively commonly used and consistently
defined. We took our definition from several publica-
tions with which we were previously familiar [1,3]. In
some of the resources the term methodological hetero-
geneity was used synonymously with clinical heterogen-
eity, or clinical heterogeneity was considered to be one
component of methodological heterogeneity. While this
was infrequent in the literature, methodological aspects
of heterogeneity include but go beyond clinical aspects
or reasons for heterogeneity between trials. Thus, when
describing reasons for heterogeneity that are related to
the participants, intervention, outcomes or settings of
the trial, these should be termed clinical aspects of het-
erogeneity. A consistency of terminology is mandatory
for development of thought and investigation in this
area. With terminology in place, the discussion can
move to our recommendations.
When planning investigations of clinical heterogeneity
in systematic reviews of controlled trials one should
make such plans explicit, a priori, in the protocol for the
review. We would suggest that protocols be published or
registered in appropriate databases [118]. Next, it is rea-
sonable and arguably beneficial, when organizing the re-
view team, to include clinical experts or at a minimum,
state a plan for consulting clinical experts during par-
ticular phases of the review (e.g., when choosing clinical
covariates or during interpretation of findings). Further-
more, a set of clinical covariates should be chosen that
have a clearly stated rationale for their importance (e.g.,
pathophysiological argument or reference to the results
of a previous large trial). Review teams should think
through the following categories to determine if related
covariates might logically influence the treatment effect
in their particular review: participant level, intervention
level, outcome level, research setting, or others unique
to the research question. Several resources offered
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as possible methods for identifying important covariates
and relationships between them [98,112,113]. Next, a
hierarchy of clinical covariates should be formed and
covariates investigated only if there is sufficient rationale
and later a sufficient number of trials available. That is,
covariates deemed more important than others on the
basis of an explicitly stated rationale should be immedi-
ately included in such investigations, with other covari-
ates being included when the number of trials is
sufficient. A generally accepted rule of thumb is that 10
events per predictor variable (EPV) maintains bias and
variability at acceptable levels. This rule derives from 2
simulation studies carried out for logistic and Cox mod-
eling strategies [119-121] and has been adapted to meta-
regression [1,114]. Therefore, it has been suggested that
for each covariate there should be at least 10 trials to
avoid potentially spurious findings [15]. Also, investiga-
tors should describe any plans to include additional
covariates after looking at the data from included stud-
ies (e.g., forest plots). This might include an examin-
ation of summary tables or various types of plots
[92,93,97,98,106], and it would be reasonable to include
the clinical expert(s) at this stage to aid in the interpret-
ation of the plotted data. Finally, how the results of any
findings are going to be interpreted and used in the
synthesis methods of the review needs to be explained.
Most resources advise caution in interpreting these
investigations, noting their exploratory nature, but when
there is a clearly stated rationale, especially when
derived from previous research, and sufficient trials are
included, a priori planned investigations may improve
applicability. Also, it was frequently suggested that the
interpretation of the results of these investigations
should consider confounds and important potential
biases, the magnitude of the effect, confidence intervals
and the directionality of the effect. Following these
recommendations may lead to valid and reliable investi-
gations of clinical heterogeneity and could improve
their overall applicability and lead to future research
that might test hypothesized subgroup effects.
A wide variety of statistical analyses are available for
investigating clinical heterogeneity in systematic reviews
of controlled clinical trials, and it is not within the
scope of this paper to cover these in detail. Other
resources cover this subject very well [15,93,95,100,114].
The sophistication of techniques is constantly growing,
and an updated, precise summary of such methods is
needed. Instead we will describe three available options
frequently suggested by resources included in our re-
view—subgroup analyses, meta-regression and the
analogue to the analysis of variance (ANOVA)—and
comment upon methods for exploring control group
event rate.Subgroup analyses involve separating trials into groups
on the basis of some characteristic (e.g., intervention
dose) and then performing separate meta-analyses for
each group. This test provides an effect estimate within
subgroups and a significance test for that estimate; it
does not provide a test of variation in effect due to cov-
ariates. The greater the number of significant tests per-
formed, the greater the likelihood of type 1 errors. There
are some suggestions in the literature for how to control
for this (e.g., Bonferroni adjustments [48]). To test for
differences between subgroups a moderator analysis
must be done. Moderator analyses include meta-
regression and the analogue to the ANOVA, among
other techniques (e.g., Z test [114]). Meta-regression is
used to assess the impact of one or more independent
variables (e.g., age or intervention dose) upon the
dependent variable, the overall treatment effect [62]. In-
dependent variables may be continuous or categorical,
the latter expressed as a set of dummy variables with
one omitted category. Several modeling strategies are
available for performing meta-regression [100,108,122].
The results of meta-regression indicate which variables
influence the summary treatment effect, how much the
summary effect changes with each unit change in the
variable and the p-value of this influence. It has been
suggested that at least 10 trials per covariate are needed
to limit spurious findings, due to the low statistical
power of meta-regression, and a nonparametric test has
been suggested when this tenet is not fulfilled [30] Also,
one needs to consider the problems associated with eco-
logical bias when performing meta-regressions on pa-
tient levels variables [40]. Finally, the analogue to the
ANOVA examines the difference in the effect between
categorical levels of some variable using identical statis-
tical methods as a standard ANOVA [94].
The literature suggests many methods for examining
the influence of the control event rate or baseline risk,
which is considered an aggregate measure of known
(e.g., age and disease severity) and unknown variables
[15,43,93]. It has been argued that these examinations
provide little import to clinical practice since the influ-
ence of any possible causative variables is aggregated
and therefore the effect of individual covariates is un-
known [15]. Also, the influence of the control event rate
on the summary affect is affected by regression to the
mean, and sophisticated statistical procedures are
required to deal with this [15,43,93].
Bayesian approaches to meta-regression and hierarch-
ical Bayes modeling, among other areas, appear to be
well represented in the literature [66,71,95], as well as
more general resources for Bayesian meta-analytic tech-
niques [95,123]. These methods are developing rapidly;
therefore, frequent summaries of these important tech-
niques are required as a resource to reviewers.
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ture concerning the utility of aggregate patient data
(APD) versus individual patient data (IPD). Several
resources give general recommendations regarding use
of IPD when exploring characteristics that could be con-
sidered aspects of clinical heterogeneity [15,74-76,95,97].
Some empirical evidence supports these recommenda-
tions [40,66,124,125]. When IPD is available, it should
be used as a basis to investigate aspects of clinical het-
erogeneity at the patient level (e.g., demographic charac-
teristics) so as to avoid ecological bias associated with
summary APD. It is reasonable to use APD for trial-level
covariates (e.g., intervention characteristics) that can be
considered aspects of clinical heterogeneity. In addition,
there may be opportunities to strategically use APD to-
gether with IPD to avoid the significant, and sometimes
insurmountable, effort required to collect complete
IPD [71].
Finally, in relation to the suggestions above for includ-
ing clinical expertise in systematic reviews, we feel it is
the responsibility of each therapeutic discipline to create
a repository of variables to consider when exploring ef-
fect variation in systematic reviews. Such warehousing of
clinically important covariates would serve as an import-
ant resource, allowing systematic reviewers and clinical
trialists to explore nuances in treatment effect that
might inform clinical decision making, and allowing for
increased applicability of findings.Conclusions
In summary, although many recommendations are
available for investigating clinical heterogeneity in sys-
tematic reviews of controlled clinical trials, there is a
need to develop a comprehensive set of recommenda-
tions for how to perform valid, applicable, and appro-
priate investigations of clinical covariates [7,14]. This
will improve the applicability and utilization of system-
atic reviews by policy makers, clinicians, and other de-
cision makers and researchers who wish to build on
these findings.Appendix A: Search strategies
1. OVID searches
Medline (1950 to Oct 29th, 2010); Cochrane Method-
ology Register (Oct 29th, 2010) ; HTA (Oct 29th, 2010);
EMBASE (1980 to Oct 30th, 2010)
“(((clinical adj5 heterogeneity)) and (assessment or
checklist or guideline or guidelines or scale or criteria))”
Note: A slight variation in this strategy was used for
EMBASE, on the EMBASE specific search engine, for an
updated search we performed from January 1st 2009 to
October 30th, 2010. This was due to a change in the
available electronic resources.2. CINAHL (EBSCO) (1981 up to October 30th, 2010):
“TX clinical N8 heterogeneity and TX ( assessment OR
checklist OR guideline OR guidelines OR scale OR cri-
teria )”
3. CONSORT database of methodological papers (up to
Oct 30th, 2010)
Manual search of all citations.
4. Related PubMed links for (completed on October 31st ,
2010):
Thompson SG. Why sources of heterogeneity in meta-
analysis should be investigated. BMJ. 1994;309:1351–5.
5. Related PubMed links for (completed on October 31st,
2010):
Higgins J, Thompson S, Deeks J, Altman D. Statistical
heterogeneity in systematic reviews of clinical trials: a
critical appraisal of guidelines and practice. Journal of
Health Services & Research Policy. Jan 2002;7(1):51–61.
6. Related PubMed links for: (completed on October 31st,
2010)
Schmid CH, Stark PC, Berlin JA, Landais P and Lau J.
Meta-regression detected associations between hetero-
geneous treatment effects and study-level, but not pa-
tient-level, factors. Journal of Clinical Epidemiology.
2004;57:683–97.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JG developed conceptualized the project, searched for the literature,
extracted data, and wrote the manuscript. DM, HB, JB and CB conceptualized
the project and edited the manuscript. All authors read and approved the
final manuscript.
Author details
1Departments of Orthopaedic Surgery and Epidemiology, University of
Michigan, 24 Frank Lloyd Wright Drive, Ann Arbor, MI, USA. 2Clinical
Epidemiology Program, Ottawa Health Research Institute, Ottawa, ON,
Canada. 3Department of Epidemiology & Community Medicine, Faculty of
Medicine, University of Ottawa, Ottawa, ON, Canada. 4Leslie Dan Faculty of
Pharmacy, University of Toronto, Toronto, ON, Canada. 5Child Health and
Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.
6Health Policy, Management & Evaluation, Faculty of Medicine, University of
Toronto, Toronto, ON, Canada.
Received: 6 September 2011 Accepted: 15 June 2012
Published: 30 July 2012
References
1. In Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1
[updated September 2008]. Edited by Higgins JPT, Green S.: The Cochrane
Collaboration; 2008. Available from www.cochrane-handbook.org.
2. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC:
Impact of allocation concealment on conclusions drawn from meta-
analyses of randomized trials. Int J Epidemiol 2007, 36(4):847–857.
3. Tugwell P, Robinson V, Grimshaw J, Santesso N: Systematic reviews and
knowledge translation. Bulletin of the World Health Organization 2006,
84:643–651.
Gagnier et al. BMC Medical Research Methodology 2012, 12:111 Page 13 of 15
http://www.biomedcentral.com/1471-2288/12/1114. Grimshaw JM, Santesso N, Cumpston M, Mayhew A, McGowan J:
Knowledge for knowledge translation: the role of the cochrane
collaboration. J Contin Educ Health Prof 2006, 26:55–62.
5. British Medical Journal, Clinical Evidence; 2009. Available at: http://
clinicalevidence.bmj.com/ceweb/about/index.jsp. Accessed February 16,
2009.
6. Canadian Institutes of Health Research. Available at: http://www.cihr-irsc.gc.ca/e/
193.html. Accessed February 16, 2009.
7. Cochrane Collaboration, Current News; Available at: http://cochrane.org/
archives/channel_2.htm. Accessed February 16, 2009.
8. Laupacis A, Strauss S, Systematic reviews: Time to address clinical and
policy relevance as well as methodological rigor. Ann Int Med 2007,
147(4):273–275.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group: Preferred
reporting items for systematic review and meta-analyses: the PRISMA
statement. PLoS Medicine 2009, 6(&):e1000097.
10. Glasziou P, Meats E, Heneghan C, Shepperd S: What is missing from
descriptions of treatment in trials and reviews? BMJ 2008, 336:1472–1474.
11. Glasziou P, Chalmers I, Altman DG, et al: Taking healthcare interventions
from trial to practice. BMJ 2010, 341:384–387.
12. Chalmers I, Glasziou P: Avoidable waste in the production and reporting
of research evidence. Lancet 2009, 374:86–89.
13. Chalmers I, Glasziou P: Avoidable waste in the production and reporting
of research evidence. Obstet Gynecol 2009, 114(6):1341–1345.
14. Scott NA, Moga C, Barton P, Rashiq S, Schopflocher D, Taenzer P, Alberta
Ambassador Program Team, et al: Creating clinically relevant knowledge
from systematic reviews: The challenges of knowledge translation. J Eval
Clin Pract 2007, 13(4):681–688.
15. Gagnier JJ, Bombardier C, Boon H, Moher D, Beyene J: An empirical study
using permutation-based resampling in meta-regression. Systematic
Reviews 2012, 1:18.
16. Gagnier JJ, Morgenstern H, Moher D: Recommendations for investigating
clinical heterogeneity in systematic reviews and meta-analyses. 2012,
Under Review.
17. Arends LR, Hoes AW, Lubsen J, Grobbee DE, Stijnen T: Baseline risk as
predictor of treatment benefit: Three clinical meta-re-analyses. Stat Med
2000, 19:3497–3518.
18. Higgins J, Thompson S, Deeks J, Altman D: Statistical heterogeneity in
systematic reviews of clinical trials: a critical appraisal of guidelines and
practice. J Health Serv Res Policy 2002, 7(1):51–61.
19. Schmid CH, Lau J, McIntosh MW, Cappelleri JC: An empirical study of the
effect of the control rate as a predictor of treatment efficacy in
meta-analysis of clinical trials. Stat Med 1998, 17(17):1923–1942.
20. Thompson SG: Why sources of heterogeneity in meta-analysis should be
investigated. BMJ 1994, 309(6965):1351–1355.
21. van den Ende CHM, Steultjens EMJ, Bouter LM, Dekker J: Clinical
heterogeneity was a common problem in Cochrane reviews of
physiotherapy and occupational therapy. J Clin Epidemiol 2006,
59:914–919.
22. Loke YK, Price D, Herxheimer A: Systematic reviews of adverse effects:
framework for a structured approach. BMC Med Res Methodol 2007, 7:32.
23. Freemantle N, Mason J, Eccles M: Deriving treatment recommendations
from evidence within randomized trials. The role and limitation of
meta-analysis. Int J Technol Assess Health Care 1999, 15(2):304–315.
24. Huang JQ, Zheng GF, Irvine EJ, Karlberg J: Assessing heterogeneity in
meta-analyses of Helicobacter pylori infection-related clinical studies: a
critical appraisal. Chin J Dig Dis 2004, 5(3):126–133.
25. Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic
reviews. Ann Intern Med 1997, 127(9):820–826.
26. Bender R, Bunce C, Clarke M, et al: Attention should be given to
multiplicity issues in systematic reviews. J Clin Epidemiol 2008,
61(9):857–865.
27. van Tulder M, Furlan A, Bombardier C, Bouter L: Updated method
guidelines for systematic reviews in the Cochrane collaboration back
review group. Spine 2003, 28(12):1290–1299.
28. Anello C, Fleiss JL: Exploratory or analytic meta-analysis: should we
distinguish between them? J Clin Epidemiol 1995, 48(1):109–116. discussion
117-108.
29. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG:
Meta-analysis of individual patient data from randomized trials: a review
of methods used in practice. Clin Trials 2005, 2(3):209–217.30. Maxwell L, Santesso N, Tugwell PS, Wells GA, Judd M, Buchbinder R:
Method guidelines for Cochrane Musculoskeletal Group systematic
reviews. J Rheumatol 2006, 33(11):2304–2311.
31. Higgins JP, Thompson SG: Controlling the risk of spurious findings from
meta-regression. Stat Med 2004, 23(11):1663–1682.
32. Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR: Methods for
exploring heterogeneity in meta-analysis. Eval Health Prof 2001,
24(2):126–151.
33. Glenton C, Underland V, Kho M, Pennick V, Oxman AD: Summaries of
findings, descriptions of interventions, and information about adverse
effects would make reviews more informative. J Clin Epidemiol 2006,
59(8):770–778.
34. Dohoo I, Stryhn H, Sanchez J: Evaluation of underlying risk as a source of
heterogeneity in meta-analyses: a simulation study of Bayesian and
frequentist implementations of three models. Prev Vet Med 2007,
81(1–3):38–55.
35. Hall JA, Rosenthal R: Interpreting and evaluating meta-analysis. Eval Health
Prof 1995, 18(4):393–407.
36. Gerbarg ZB, Horwitz RI: Resolving conflicting clinical trials: guidelines for
meta-analysis. J Clin Epidemiol 1988, 41(5):503–509.
37. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7(3):177–188.
38. St-Pierre NR: Invited review: Integrating quantitative findings from
multiple studies using mixed model methodology. J Dairy Sci 2001,
84(4):741–755.
39. Cook DJ, Sackett DL, Spitzer WO: Methodologic guidelines for
systematic reviews of randomized control trials in health care from
the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol 1995,
48(1):167–171.
40. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI: Individual
patient- versus group-level data meta-regressions for the investigation
of treatment effect modifiers: ecological bias rears its ugly head. Stat
Med 2002, 21(3):371–387.
41. Walter SD: Variation in baseline risk as an explanation of heterogeneity
in meta-analysis. Stat Med 1997, 16(24):2883–2900.
42. Cheung MW: A model for integrating fixed-, random-, and mixed-effects
meta-analyses into structural equation modeling. Psychol Methods 2008,
13(3):182–202.
43. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F: Systematic reviews
of trials and other studies. Health Technol Assess 1998, 2(19):1–276.
44. Rosenthal R, DiMatteo MR: Meta-analysis: recent developments in
quantitative methods for literature reviews. Annu Rev Psychol 2001,
52:59–82.
45. Song F: Exploring heterogeneity in meta-analysis: is the L'Abbe plot
useful? J Clin Epidemiol 1999, 52(8):725–730.
46. Reade MC, Delaney A, Bailey MJ, Angus DC: Bench-to-bedside review:
Avoiding pitfalls in critical care meta-analysis–funnel plots, risk
estimates, types of heterogeneity, baseline risk and the ecologic fallacy.
Crit Care 2008, 12(4):220.
47. Xu H, Platt RW, Luo ZC, Wei S, Fraser WD: Exploring heterogeneity in
meta-analyses: needs, resources and challenges. Paediatr Perinat Epidemiol
2008, 22(Suppl 1):18–28.
48. Olkin I: Diagnostic statistical procedures in medical meta-analyses. Stat
Med 1999, 18(17–18):2331–2341.
49. Sterne JA, Egger M, Smith GD: Systematic reviews in health care:
Investigating and dealing with publication and other biases in meta-
analysis. BMJ 2001, 323(7304):101–105.
50. Lipsey MW, Wilson DB: The way in which intervention studies have
"personality" and why it is important to meta-analysis. Eval Health Prof
2001, 24(3):236–254.
51. Moher D, Jadad AR, Klassen TP: Guides for reading and interpreting
systematic reviews: III. How did the authors synthesize the data and
make their conclusions? Arch Pediatr Adolesc Med 1998, 152(9):915–920.
52. Schmid JE, Koch GG, LaVange LM: An overview of statistical issues and
methods of meta-analysis. J Biopharm Stat 1991, 1(1):103–120.
53. Berlin JA: Invited commentary: benefits of heterogeneity in meta-
analysis of data from epidemiologic studies. Am J Epidemiol 1995,
142(4):383–387.
54. Malling HJ, Thomsen AB, Andersen JS: Heterogeneity can impair the
results of Cochrane meta-analyses despite accordance with statistical
guidelines. Allergy 2008, 63(12):1643–1645.
Gagnier et al. BMC Medical Research Methodology 2012, 12:111 Page 14 of 15
http://www.biomedcentral.com/1471-2288/12/11155. Bravata DM, Shojania KG, Olkin I, Raveh A: CoPlot: a tool for visualizing
multivariate data in medicine. Stat Med 2008, 27(12):2234–2247.
56. Baujat B, Mahe C, Pignon JP, Hill C: A graphical method for exploring
heterogeneity in meta-analyses: application to a meta-analysis of 65
trials. Stat Med 2002, 21(18):2641–2652.
57. Higgins JP, Whitehead A: Borrowing strength from external trials in a
meta-analysis. Stat Med 1996, 15(24):2733–2749.
58. Michiels S, Baujat B, Mahe C, Sargent DJ, Pignon JP: Random effects
survival models gave a better understanding of heterogeneity in
individual patient data meta-analyses. J Clin Epidemiol 2005,
58(3):238–245.
59. Thompson SG, Sharp SJ: Explaining heterogeneity in meta-analysis: a
comparison of methods. Stat Med 1999, 18(20):2693–2708.
60. Smith CT, Williamson PR, Marson AG: Investigating heterogeneity in an
individual patient data meta-analysis of time to event outcomes. Stat
Med 2005, 24(9):1307–1319.
61. Simmonds MC, Higgins JP: Covariate heterogeneity in meta-analysis:
criteria for deciding between meta-regression and individual patient
data. Stat Med 2007, 26(15):2982–2999.
62. Thompson SG, Higgins JP: How should meta-regression analyses be
undertaken and interpreted? Stat Med 2002, 21(11):1559–1573.
63. Thompson SG, Smith TC, Sharp SJ: Investigating underlying risk as a
source of heterogeneity in meta-analysis. Stat Med 1997,
16(23):2741–2758.
64. Frost C, Clarke R, Beacon H: Use of hierarchical models for meta-analysis:
experience in the metabolic ward studies of diet and blood cholesterol.
Stat Med 1999, 18(13):1657–1676.
65. Naylor CD: Two cheers for meta-analysis: problems and opportunities in
aggregating results of clinical trials. Cmaj 1988, 138(10):891–895.
66. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J: Meta-regression detected
associations between heterogeneous treatment effects and study-level,
but not patient-level, factors. J Clin Epidemiol 2004, 57(7):683–697.
67. Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG: Meta-analysis
of continuous outcome data from individual patients. Stat Med 2001,
20(15):2219–2241.
68. Berkey CS, Anderson JJ, Hoaglin DC: Multiple-outcome meta-analysis of
clinical trials. Stat Med 1996, 15(5):537–557.
69. Thompson SG, Turner RM, Warn DE: Multilevel models for meta-analysis,
and their application to absolute risk differences. Stat Methods Med Res
2001, 10(6):375–392.
70. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA: A random-effects
regression model for meta-analysis. Stat Med 1995, 14(4):395–411.
71. Warn DE, Thompson SG, Spiegelhalter DJ: Bayesian random effects
meta-analysis of trials with binary outcomes: methods for the
absolute risk difference and relative risk scales. Stat Med 2002,
21(11):1601–1623.
72. Nixon RM, Bansback N, Brennan A: Using mixed treatment comparisons
and meta-regression to perform indirect comparisons to estimate the
efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007,
26(6):1237–1254.
73. Koopman L, van der Heijden GJ, Glasziou PP, Grobbee DE, Rovers MM: A
systematic review of analytical methods used to study subgroups in
(individual patient data) meta-analyses. J Clin Epidemiol 2007,
60(10):1002–1009.
74. Riley RD, Lambert PC, Staessen JA, et al: Meta-analysis of continuous
outcomes combining individual patient data and aggregate data. Stat
Med 2008, 27(11):1870–1893.
75. Thompson SG, Higgins JP: Treating individuals 4: can meta-analysis help
target interventions at individuals most likely to benefit? Lancet 2005,
365(9456):341–346.
76. Trikalinos TA, Ioannidis JP: Predictive modeling and heterogeneity of
baseline risk in meta-analysis of individual patient data. J Clin Epidemiol
2001, 54(3):245–252.
77. Knapp G, Hartung J: Improved tests for a random effects meta-regression
with a single covariate. Stat Med 2003, 22(17):2693–2710.
78. van Houwelingen HC, Arends LR, Stijnen T: Advanced methods in
meta-analysis: multivariate approach and meta-regression. Stat Med 2002,
21(4):589–624.
79. Sharp SJ, Thompson SG: Analysing the relationship between treatment
effect and underlying risk in meta-analysis: comparison and
development of approaches. Stat Med 2000, 19(23):3251–3274.80. Ghidey W, Lesaffre E, Stijnen T: Semi-parametric modelling of the
distribution of the baseline risk in meta-analysis. Stat Med 2007,
26(30):5434–5444.
81. Cook RJ, Walter SD: A logistic model for trend in 2 x 2 x kappa
tables with applications to meta-analyses. Biometrics 1997,
53(1):352–357.
82. Chang BH, Waternaux C, Lipsitz S: Meta-analysis of binary data:
which within study variance estimate to use? Stat Med 2001,
20(13):1947–1956.
83. Davey Smith G, Egger M, Phillips AN: Meta-analysis. Beyond the grand
mean? BMJ 1997, 315(7122):1610–1614.
84. Sidik K, Jonkman JN: A note on variance estimation in random effects
meta-regression. J Pharm Stat 2005, 15:823–838.
85. Sutton A: Recent development in meta-analysis. Stat Med 2008,
27:625–650.
86. Bagnardi V, Quatto P, Corrao G: Flexible meta-regression functions for
modelling aggregate dose-response data, with an application to alcohol
and mortality. Am J Epidemiol 2004, 159(11):1077–1086.
87. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency
in meta-analyses. BMJ 2007, 327:557–560.
88. Ioannidis JP: Interpretation of test of heterogeneity and bias in
meta-analysis. J Eval Clin Pract 2008, 14:951–957.
89. Glasziou PP, Sanders SL: Investigating causes of heterogeneity in
systematic reviews. Stat Med 2002, 21:1503–11.
90. Hatala R, Wyer P, Guyatt G, for the Evidence-Based Medicine Teaching
Tips Working Group: Tips for learners of evidence-based medicine:
4. Assessing heterogeneity of primary studies in systematic reviews
and whether to combine their results. CMAJ 2005, 172(5):661–665.
91. Bailey KR: Inter-study differences: How should they influence the
interpretation and analysis of results? Stat Med. 1987, 6:351–358.
92. Khalid S, Khan RK, Kleijnen J, Antes G: Systematic Reviews to Support
Evidence-based Medicine: How to Apply Findings of Health-Care Research.
London: Royal Society of Medicine Press Ltd.; 2003.
93. Sutton AJ, Jones DR, Sheldon TA, Song F: Methods for Meta-analysis in
Medical Research. Chichester: John Wiley & Sons, Ltd.; 2000.
94. Littell JC, Corcoran J, Pillai VK: Systematic Reviews and Meta-Analysis. Oxford:
Oxford University Press; 2008.
95. Whitehead A: Meta-Analysis of Controlled Clinical Trials. Chichester: John
Wiley & Sons, Ltd.; 2002.
96. Furlan AD, Pennick V, Bombarider C, van Tulder M, from the Editorial Board
of the Cochrane Back Review Group: 2009 Updated method guidelines for
systematic reviews in the Cochrane back review group. Spine 2009,
34(18):1929–1941.
97. National Health and Medical Research Council: How to Review the Evidence:
Systematic Identification and Review of the Scientific Literature. Australia:
Commonwealth of Australia; 2000.
98. Centre for Reviews and Dissemination: CRD’s Guidance for Undertaking
Reviews in Health Care. York: CRD; 2009.
99. Oxman AD, Guyatt GH: A consumer's guide to subgroup analyses. Ann
Intern Med 1992, 116(1):78–84.
100. In Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0
[updated September 2008]. Edited by Higgins JPT, Green S.: The Cochrane
Collaboration; 2008. Available from: www.cochrane-handbook.org.
101. Imperiale TF: Meta-analysis: when and how. Hepatology 1999,
29(6 Suppl):26S–31S.
102. Shekelle PG, Morton SC: Principles of metaanalysis. J Rheumatol 2000,
27(1):251–252. discussion 252-53.
103. Nagin DS, Odgers CL: Group-based trajectory modeling in clinical
research. Annu Rev Clin Pscyhol. 2010, 6:109–138.
104. Virgile G, Conto AA, Moja L, Gensini GL, Gusinu R: Heterogeneity and
meta-analyses: do study results truly differ? Intern Emerg Med 2009,
4:423–427.
105. Skipka G, Bender R: Intervention effects in the case of heterogeneity
between three subgroups: Assessment within the framework of
systematic reviews. Methods Inf Med. 2010, 49:613–617.
106. Groenwold RHH, Rovers MM, Lubsen J, van der Heijden JMG: Subgroup
effects despite homogenous heterogeneity test results. BMC Medical
Research Methodology. 2010, 10:43.
107. Lockwood CM, DeFrancesco CA, Elliot DL, Beresford SAA, Toobert DJ:
Mediation analyses: Applications in nutrition research and reading the
literature. J Am Diet Assoc 2010, 110:753–763.
Gagnier et al. BMC Medical Research Methodology 2012, 12:111 Page 15 of 15
http://www.biomedcentral.com/1471-2288/12/111108. Baker W, White M, Cappelleri JC, Kluger J, Colman CI: Understanding
heterogeneity in meta-analysis: the role of meta-regression. Int J Clin
Pract 2009, 63(10):1426–1434.
109. Jones AP, Riley RD, Williamson PR, Whitehead A: Meta-analysis of
individual patient data versus aggregate data from longitudinal clinical
trials. Clin Trials 2009, 6:16–27.
110. Hemming K, Hutton JL, Maguire MJ, Marson AG: Meta-regression with
partial information on summary trial or patient characteristics. Stat Med
2008, 29:1312–1324.
111. Salanti G, Marinho V, Higgins JPT: A case study of multiple-treatments
meta-analysis demonstrates covariates should be considered. J Clin
Epidemiol 2009, 62:857–864.
112. Glasziou P, Chalmers I, Altman DG, Bastian H, Boutron I, Brice A, et al:
Taking healthcare interventions from trial to practice. BMJ 2010,
341:c3852.
113. Shadish WR: Meta-analysis and the exploration of causal mediating
processes: A primer of examples, methods, and issues. Psychol Methods
1996, 1:47–65.
114. Borenstein MA, Hedges LV, Higgins JPT, Rothstein HR: Introduction to
Meta-Analysis. New Jersey: John Wiley and Sons; 2009.
115. West SL, Gartlehner G, Mansfield AJ, et al: Comparative effectiveness review
methods: clinical heterogeneity, In: Agency for Healthcare Research and
Quality. Comparative Effectiveness Review Methods: Clinical Heterogeneity.
Rockville, MD:; Posted 09/28/2010. Available at http://effectivehealthcare.
ahrq.gov/.
116. McIntosh MW: The population risk as an explanatory variable in research
synthesis of clinical trials. Stats Med 1996, 15:1713–1728.
117. Boutitie F, Gueyffier F, Pocock SJ, Biossel JP: Assessing treatment-time
interaction in clinical trials with time to event data: A meta-analysis of
hypertension trials. Stat Med 1998, 17:2883–2903.
118. Booth A, Clarke M, Ghersi D, MOher D, Petticrew M, Stewart L: An
international registry of systematic-review protocols. Lancet 2011,
377(9760):108–109.
119. Concato J, Peduzzi P, Holfold TR, et al: Importance of events per
independent variable in proportional hazards analysis. I. Background,
goals, and general strategy. J Clin Epidemiol 1995, 48:1495–1501.
120. Peduzzi P, Concato J, Feinstein AR, et al: Importance of events per
independent variable in proportional hazards regression analysis. II.
Accuracy and precision of regression estimates. J Clin Epidemiol 1995,
48:1503–1510.
121. Peduzzi P, Concato J, Kemper E, et al: A simulation study of the number of
events per variable in logistic regression analysis. J Clin Epidemiol 1996,
49:1373–1379.
122. Harrell FE: Regression Modeling Strategies: With Applications to Linear Models,
Logistic Regression, and Survival Analysis. New York: Springer; 2001.
123. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR: Bayesian methods in
health technology assessment: A review. Health Technol Assess 2000,
4:1–130.
124. Smith CT, Williamson PR, Marson AG: An overview of methods and
empirical comparison of aggregate data and individual patient data
results for investigating heterogeneity in meta-analysis to time-to-event
data. J Eval Clin Pract 2002, 55:86–94.
125. Lambert PC, Sutton AJ, Jones ADR: A comparison of patient-level
covariates in meta-regression with individual patient data meta-analysis.
J Clin Epidemiol 2002, 55:86–94.
doi:10.1186/1471-2288-12-111
Cite this article as: Gagnier et al.: Investigating clinical heterogeneity in
systematic reviews: a methodologic review of guidance in the literature.
BMC Medical Research Methodology 2012 12:111.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
